Related Experiment Video
Updated: May 23, 2026
04:19
The Establishment of a Murine Mandibular Molar Extraction Socket Healing Model
Published on: January 13, 2023
Tooth extraction in patients on zoledronic acid therapy
Marco Mozzati1, Valentina Arata, Giorgia Gallesio
1Department of Clinical Physiopathology, Oral Surgery Unit, Dentistry Section, University of Turin, Turin 10126, Italy. marco.mozzati@libero.it
Oral Oncology
|April 10, 2012
Summary
Plasma Rich in Growth Factor (PRGF) may reduce the risk of medication-related osteonecrosis of the jaw (BRONJ) in patients undergoing dental extractions after bisphosphonate therapy. This growth factor preparation aids in healing and restoring bone health.
Area of Science:
- Oral Surgery
- Biomaterials Science
- Oncology
Background:
- Surgical management of patients on zoledronic acid therapy is challenging.
- Dental extractions are a primary cause of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Purpose of the Study:
- To evaluate the efficacy of Plasma Rich in Growth Factor (PRGF) in preventing BRONJ.
- To assess the impact of PRGF on patients undergoing dental extractions while on bisphosphonate therapy.
Main Methods:
- A case-control study involving 176 patients on intravenous bisphosphonates for oncologic conditions who underwent dental extractions.
- Patients were randomly assigned to receive PRGF treatment (study group, n=91) or no PRGF treatment (control group, n=85).
- Radiological assessments (panoramic X-ray, CT) were conducted pre- and post-surgery (60 months).
Main Results:
- BRONJ was diagnosed in 5 patients within the control group.
- The average time to BRONJ diagnosis in the control group was 91.6 days post-extraction.
Conclusions:
- PRGF may facilitate the restoration of osteoblast/osteoclast balance through autologous cytokines.
- This protocol potentially reduces the incidence of BRONJ in patients requiring dental extractions during bisphosphonate treatment.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...